| 范立侨,夏宇翔,檀碧波.苹果酸舒尼替尼二线治疗37例晚期胃肠间质瘤的临床研究[J].肿瘤学杂志,2021,27(6):455-458. |
| 苹果酸舒尼替尼二线治疗37例晚期胃肠间质瘤的临床研究 |
| Sunitinib Malate as Second-line Therapy for Advanced Gastrointestinal Stromal Tumor：An Analysis of 37 Cases |
| 投稿时间：2021-02-22 |
| DOI：10.11735/j.issn.1671-170X.2021.06.B008 |
|
 |
| 中文关键词: 胃肠间质瘤 苹果酸舒尼替尼 无进展生存期 总生存期 不良反应 |
| 英文关键词:gastrointestinal stromal tumor sunitinib malate PFS OS adverse reactions |
| 基金项目:河北省科技厅课题（14277751D） |
|
| 摘要点击次数: 1115 |
| 全文下载次数: 269 |
| 中文摘要: |
| 摘 要：［目的］ 探讨苹果酸舒尼替尼二线治疗晚期胃肠间质瘤(GIST)患者的临床疗效及其不良反应。［方法］ 选取河北医科大学第四医院应用苹果酸舒尼替尼二线治疗的37例晚期胃肠间质瘤患者的临床资料，进行回顾性分析，按Choi标准进行疗效评估。［结果］ 37例患者共接受苹果酸舒尼替尼治疗701个月，平均18.9个月。治疗后PR 4例（10.8%）、SD 17例（45.9%）、PD 16例（32.4%），总体客观有效率（ORR）为10.8%，疾病控制率（DCR）为56.8%。不良反应多为1～2级，3～4级较少，无5级不良反应。肝转移组中位无进展生存期（PFS）为18.0个月，较腹腔转移组（8.5个月）明显增加（P＜0.05）；c-kit外显子11突变组PFS为14.0个月，较外显子9突变组（15.0个月）降低（P＜0.05）。［结论］ 苹果酸舒尼替尼二线治疗GIST可提高DCR，延长PFS，其对单纯肝转移者及c-kit 9外显子突变者疗效更加显著，不良反应可耐受。 |
| 英文摘要: |
| Abstract：［Objective］ To investigate the clinical efficacy and safety of sunitinib malate as second-line therapy for patients with advanced gastrointestinal stromal tumor(GIST). ［Methods］ The clinical data of 37 patients with advanced GIST treated with sunitinib malate as second-line therapy in the Fourth Hospital of Hebei Medical University from January 2003 to December 2018 were retrospectively analyzed. The efficacy was evaluated according to Choi standard. ［Results］ Patients received the treatment of sunitinib malate with an average of 18.9 months. There were 4 cases of PR(10.8%)，17 cases of SD(45.9%) and 16 cases of PD(32.4%). The overall objective response rate(ORR) was 10.8%，and the disease control rate(DCR) was 56.8%. The adverse drug reactions were mostly grade 1~2，and no grade 5 adverse drug reactions was observed. The PFS of liver metastasis group was significantly higher than that of abdominal metastasis group(18.0 months vs 8.5 months，P<0.05)；the PFS of c-kit exon 11 mutation group was lower than that of exon 9 mutation group(14.0 months vs 15.0 months，P<0.05). ［Conclusion］ Sunitinib malate may improve DCR and prolong PFS in patients with advanced GSIT. The curative effect is more significant in patients with simple liver metastasis and c-kit exon 9 mutation，and adverse reactions are tolerable. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |